Key Takeaways
- RKLB shares advanced approximately 7% Monday following Cantor Fitzgerald’s Buy rating reiteration
- The company’s June 22 entry into the Nasdaq-100 Index identified as a significant driver for passive investment inflows
- KeyBanc initiated Overweight coverage with a $135 target, pointing to more than 30% potential gains
- Analysts attribute the recent decline to capital flows related to SpaceX’s Nasdaq listing rather than operational concerns
- Consensus among Wall Street analysts remains Strong Buy with a mean target of $108.70 and peak forecast at $150
Rocket Lab (RKLB) shares climbed approximately 7% during Monday’s trading session after receiving positive attention from two Wall Street firms. Cantor Fitzgerald maintained its Overweight stance, while KeyBanc delivered a new upgrade — offering investors compelling reasons to consider the stock following its 11% decline on June 12.
The stock currently trades roughly 27% below its year-to-date peak reached in late May.
Cantor Fitzgerald’s Andres Sheppard emphasized June 22 as a pivotal milestone. This date marks Rocket Lab’s formal addition to the Nasdaq-100 Index. The inclusion elevates the company’s visibility among institutional capital and compels index-tracking funds and ETFs to acquire shares.
Sheppard characterized the Nasdaq-100 addition as “material” — an assessment that appears well-founded given the circumstances.
Beyond index inclusion, Sheppard identified what he termed “material moats” distinguishing Rocket Lab from emerging rivals. These advantages encompass an established history of successful launches, a three-vehicle portfolio (Electron, HASTE, and the forthcoming Neutron), a diversified customer base spanning commercial and government sectors, and launch facilities located in both New Zealand and the United States.
Sheppard holds the 1,456th position among more than 12,200 analysts monitored by TipRanks, achieving a 100% success rate on RKLB predictions and delivering an average return of 196.92% per recommendation over one year.
KeyBanc Makes the Bull Case
KeyBanc’s Michael Leshock initiated coverage with an Overweight rating and $135 price objective — suggesting upside exceeding 30% from the prior closing price. His investment thesis rests on the premise that recent share weakness stemmed from market dynamics rather than operational deterioration.
When SpaceX completed its landmark Nasdaq listing, institutional portfolios rushed to establish positions in the newly traded aerospace powerhouse. This prompted selling of existing space-sector holdings — Rocket Lab among them. Leshock characterized it as rotation-driven selling pressure, not a fundamental deterioration.
He emphasized a persistent structural deficit in launch capacity that he anticipates will keep supply constrained for more than a decade. Expanding demand for satellite networks and growing global military investment in space capabilities reinforce this outlook.
Rocket Lab concluded the first quarter with a backlog surpassing $2.2 billion. The firm is also competing for significant contracts including NASA’s Mars Telecommunications Orbiter initiative.
Vertical Integration Provides Competitive Advantage
Leshock underscored Rocket Lab’s vertically integrated approach as a critical competitive differentiator. With approximately 90 successful Electron missions completed and increasing visibility into its Neutron medium-lift vehicle development, he noted the company demonstrates “institutional-grade” operational excellence.
He believes RKLB is protecting itself from the typical risks facing small-launch operators by controlling more of its supply chain — an approach that echoes SpaceX’s proven strategy.
Wall Street analysts generally regard Rocket Lab as the definitive second-place competitor in commercial space behind SpaceX.
The consensus analyst rating on RKLB stands at Strong Buy, reflecting 10 Buy recommendations and three Hold ratings. The mean price objective reaches $108.70, while the highest target stands at $150 — indicating approximately 37% upside potential from present levels.
